Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Saved in:
| Title: | Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. |
|---|---|
| Authors: | Aamdal E; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Ellingsen EB; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Rasch W; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Brunsvig PF; Department of Oncology, Oslo University Hospital, Oslo, Norway., Aamdal S; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Heintz KM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Vodák D; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Nakken S; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Hovig E; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway., Nyakas M; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Guren TK; Department of Oncology, Oslo University Hospital, Oslo, Norway., Gaudernack G; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway. |
| Source: | Frontiers in immunology [Front Immunol] 2021 May 11; Vol. 12, pp. 663865. Date of Electronic Publication: 2021 May 11 (Print Publication: 2021). |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
